SYN. Synthetic Biologics Initiates Development of Monoclonal Antibodies for Treatment of Acinetobacter Infections -- Acinetobacter Infections Pose Growing Concern in Hospitals, and in Military and Natural Disaster Trauma Centers -- -- Company Engages Former Pfizer/Wyeth Global Infectious Disease Pharmaceutical Executive to Provide Expertise on Advancing Infectious Disease Pipeline -- http://finance.yahoo.com/news/synthetic-biologics-initiates-development-monoclonal-110000638.html